Physicochemical characterization of ferric pyrophosphate citrate

por Gupta, Ajay, Pratt, Raymond, Mishra, Bhoopesh
Publicado 2018

A confusional state associated with use of lanthanum carbonate in a dialysis patient: a case report

por Smyth, Michael D. L., Pratt, Raymond D.
Publicado 2009

Comment on: ‘Lanthanum carbonate possibly responsible for acute liver failure in a patient with Child–Pugh stage A liver cirrhosis’

por Smyth, Michael, Gellert, Birgitt, Pratt, Raymond D.
Publicado 2009

Ferrous iron content of intravenous iron formulations

por Gupta, Ajay, Pratt, Raymond D., Crumbliss, Alvin L.
Publicado 2016

Pharmacokinetics of Ferric Pyrophosphate Citrate, a Novel Iron Salt, Administered Intravenously to Healthy Volunteers

por Pratt, Raymond D., Swinkels, Dorine W., Ikizler, T. Alp, Gupta, Ajay
Publicado 2016

Ferric pyrophosphate citrate: interactions with transferrin

por Pratt, Raymond, Handelman, Garry J., Edwards, Thomas E., Gupta, Ajay
Publicado 2018

Pharmacokinetics of ferric pyrophosphate citrate administered via dialysate and intravenously to pediatric patients on chronic hemodialysis

por Pratt, Raymond D., Grimberg, Sarah, Zaritsky, Joshua J., Warady, Bradley A.
Publicado 2018

Ferric pyrophosphate citrate administered via dialysate reduces erythropoiesis-stimulating agent use and maintains hemoglobin in hemodialysis patients

por Gupta, Ajay, Lin, Vivian, Guss, Carrie, Pratt, Raymond, Ikizler, T Alp, Besarab, Anatole
Publicado 2015

Pharmacokinetics and Safety of Intravenous Ferric Pyrophosphate Citrate: Equivalence to Administration via Dialysate

por Marbury, Thomas, van Heuveln, Fred, van der Horst, Eric, Pratt, Raymond D.
Publicado 2022

Ferric pyrophosphate citrate (Triferic™) administration via the dialysate maintains hemoglobin and iron balance in chronic hemodialysis patients

por Fishbane, Steven N., Singh, Ajay K., Cournoyer, Serge H., Jindal, Kailash K., Fanti, Paolo, Guss, Carrie D., Lin, Vivian H., Pratt, Raymond D., Gupta, Ajay
Publicado 2015

Pharmacokinetics and Safety of Ferric Pyrophosphate Citrate in Chinese Subjects with and without Hemodialysis-Dependent Stage 5 Chronic Kidney Disease

por Gan, Liangying, Xie, Panpan, Tan, Yan, Wei, Gang, Yuan, Xiaojuan, Lu, Zhifei, Pratt, Raymond, Zhou, Yongchun, Hui, Ai-Min, Li, Kexin, Fang, Yi, Zuo, Li
Publicado 2022

Ethnicity evaluation of ferric pyrophosphate citrate among Asian and Non-Asian populations: a population pharmacokinetics analysis

por Zhang, Lingxiao, Gan, Liangying, Li, Kexin, Xie, Panpan, Tan, Yan, Wei, Gang, Yuan, Xiaojuan, Pratt, Raymond, Zhou, Yongchun, Hui, Ai-Min, Fang, Yi, Zuo, Li, Zheng, Qingshan
Publicado 2022